Marksans Pharma’s wholly owned subsidiary -- Bell Sons & Co. (Druggists) has received UK MHRA’s grant for market authorization of Bells Healthcare All in One Oral Solution. Marksans will manufacture the products at its UK MHRA approved facility Bell Sons & Co. (Druggists) in UK. This is first generic approval by UK MHRA for the product.
Each 20 ml dose contains Paracetamol Ph. Eur. 500.0 mg, Guaifenesin Ph. Eur. 200.0 mg and Phenylephrine Hydrochloride Ph. Eur. 10.0 mg. Therapeutic use of the product is for short term symptomatic relief of colds, chills and influenza including chesty coughs.
Marksans Pharma together with its subsidiaries operates as an integrated international pharmaceutical company. The company’s business is distribution of pharmaceutical products.
